Overview

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs (OADs). This study also investigates the augment effect of repaglinide on the phases of insulin secretion as a subgroup study.

Phase:

Phase 4

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Gliclazide
Hypoglycemic Agents
Repaglinide